Photosoft compounds demonstrated ≥99% inhibition against Zika virus in cell-based assays following the application of light. Zika virus is found in 86 countries and has been linked to birth defects and other neurological complications. The Zika virus market is to be worth ~US$17 billion in 2022 with no treatments for the disease currently available. Several…
Read more
INV043 Significantly Improved Checkpoint Inhibitor Therapy
Combination therapy of INV043 and immune checkpoint inhibitors ("ICI") shown to be more effective compared to standalone ICI therapy, resulting in ~65% reduction of tumour size in mice. Despite widespread clinical use as a monotherapy, ICI's effectiveness is typically limited to a smaller proportion of the cancer patient population. (more…)
Read more
PROOF OF CONCEPT III – Combination with Immune Checkpoint Inhibitors (ICI)
INVION | PoC III: COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS Melbourne (Australia) 30 May 2022: Invion Limited (ASX: IVX) is please to announce the findings from the third Proof-Of-Concept (PoC) study undertaken by its research partner, Hudson Institute of Medical Research (Hudson Institute). The PoC was specifically designed to evaluate whether INV043 can be used in…
Read more
Cho Group Chairman wins defamation suit against uSpiked editor
CHO GROUP | PRESS RELEASE Cho Group Chairman wins defamation suit against uSpiked editor Queensland court finds gossip website editor-in-chief defamed Michael Cho Defendant ordered to pay $350,000 in damages to Mr Cho Court issued an injunction restraining the defendant from publishing or republishing the defamatory articles or articles with similar content Melbourne, Australia –…
Read more